Compare Illumina, Inc. (ILMN) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs KKR & Co Inc — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while KKR & Co Inc trades at $90.95 (market cap $80.39B). The key difference: KKR & Co Inc is far larger — about 2× Illumina, Inc.'s market cap, and KKR & Co Inc pays a 0.87% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and KKR & Co Inc for 67 Days on average.
| ILMN | KKR | |
|---|---|---|
Market Cap | $39.95B | $80.39B |
Volume | 3,169,503 | 6,517,705 |
Sector | Health | Financials |
52-Week High | $293.69 | $142.75 |
52-Week Low | $91.00 | $83.88 |
Typical Hold Time | 83 Days | 67 Days |
Enterprise Value | $41.31B | $2.95B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
KKR trades at $89.56, down 0.12% with bearish technical signals despite strong analyst support. The company reported mixed quarterly results with Q2 2026 EPS beating expectations at $1.63 versus $1.43 estimate, while Q4 2025 missed. Recent business activity includes joint ventures with Thomson Reuters and Realty Income, plus multiple asset sales in Asia. Financial trends show revenue stabilizing around $19-21B with net margins improving to 14.96% projected for 2026.
The investment case balances strong Wall Street bullishness (88.9% buy ratings, $123.30 consensus target) against technical weakness and volatile cash flows. Key opportunities include continued earnings beats and strategic partnerships, while risks involve significant debt levels and market-sensitive investment returns. The stock presents a value gap if fundamentals can overcome current technical pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
